It was a relatively small study, and patients were only followed for six months, but these late-breaking data out of ESC Congress 2026 give care teams a lot to consider. 

New data presented at ESC Congress 2026 represent a huge breakthrough for patients with nonobstructive HCM. "For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease," one researcher explained. 

Many patients who need TAVR also present with coronary artery disease. According to new data presented at ESC Congress 2026, performing TAVR first is noninferior to performing PCI first. 

“Our findings do not support routine electrical mapping to target left ventricular lead placement in contemporary CRT practice,” one researcher said. 

While T-TEER is already known to improve a patient's quality of life, this late-breaking study from ESC Congress 2026 confirmed it also improves survival and reduces the risk of heart failure hospitalization.

AI technology developed by Caristo Diagnostics was the focus of multiple studies presented at ESC Congress 2026.

The issue, brought on by a manufacturing defect, has been linked to two serious injuries. The FDA shared an early alert about the situation as it continues its investigation. 

Each system is powered by GE HealthCare's cSound imaging architecture and includes advanced AI capabilities.

The new guidelines, published in European Heart Journal and presented at ESC Congress 2026, show just how much heart failure care has evolved in recent years.

AI-powered software from Heartflow can provide cath labs with a lot of value, according to new late-breaking data presented at ESC Congress 2026.

More than 95% of congenital heart patients now survive into adulthood, leaving clinicians with much more ground to cover than ever before. Providing high-quality care for these patients requires specialty care as well as collaborations with general cardiologists.

The popular diabetes drug, sold by Eli Lilly and Company under the brand name Mounjaro, has been at the center of many cardiology trials over the years. It is the first dual GIP and GLP-1 hormone receptor agonist approved by the FDA for this indication.

The imaging agent could offer a new approach for diagnosing stiff heart syndrome, according to data presented during the European Society of Cardiology Congress. 

Unsurprising but noteworthy: Judging by the ages of doctors who are all in with AI in 2026—and the ages of those who aren’t—the technology remains more a thing of the future than of the present.